Tags

Type your tag names separated by a space and hit enter

Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study.
Hum Reprod. 2005 Apr; 20(4):894-9.HR

Abstract

BACKGROUND

Elevated levels of plasma homocysteine (Hcy) have been implicated as a significant risk factor for cardiovascular disease. Although long-term treatment with metformin can increase Hcy levels in patients with type II diabetes mellitus or coronary heart disease, it is becoming an increasingly accepted and widespread medication in polycystic ovary syndrome (PCOS). In the literature, only one study has demonstrated that metformin increases Hcy levels in PCOS patients, but the effect of other insulin sensitizers on Hcy levels have not been reported previously in women with PCOS. We aimed to assess the effects of metformin and rosiglitazone on plasma Hcy levels in patients with PCOS.

METHODS

Thirty women were randomized to two groups: 15 women in group 1 received 850 mg of metformin twice daily for 3 months. In group 2, 15 women received 4 mg of rosiglitazone for 3 months. In both groups, body mass index, menstrual pattern, and plasma total Hcy, insulin, glucose and lipid metabolism parameters were recorded at baseline and at 3 months.

RESULTS

Hcy levels increased from 8.93+/-0.49 to 11.26+/-0.86 micromol/l (P = 0.002) and from 10.70+/-0.86 to 12.36+/-0.81 micromol/l (P = 0.01) in the metformin and rosiglitazone groups, respectively. Apolipoprotein (Apo) A1 levels increased from 127.10+/-6.85 to 145.7+/-7.18 mg/dl (P = 0.018) in the metformin group. Total cholesterol (total-C), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), lipoprotein (a) and Apo B levels decreased in the metformin group, but the change was not significant. Total-C levels decreased from 161.15+/-8.94 to 150.23+/-8.73 mg/dl (P = 0.026), HDL-C decreased from 43.13+/-2.65 to 39.15+/-2.52 mg/dl (P = 0.005) and LDL-C levels decreased from 93.83+/-6.06 to 80.7+/-2.30 mg/dl (P = 0.021) in the rosiglitazone group.

CONCLUSION

Treatment with insulin sensitizers in women with PCOS may lead to increases in Hcy levels.

Authors+Show Affiliations

Kilicdag EB
Baskent University Faculty of Medicine, Department of Obstetrics and Gynecology, Adana, Turkey. esrabulgan1972@mynet.com
Bagis T
No affiliation info available
Zeyneloglu HB
No affiliation info available
Tarim E
No affiliation info available
Aslan E
No affiliation info available
Haydardedeoglu B
No affiliation info available
Erkanli S
No affiliation info available

MeSH

AdultAnovulationBlood GlucoseBody WeightFemaleFolic AcidHomocysteineHumansHypoglycemic AgentsInsulin ResistanceLipidsLuteinizing HormoneMetforminPolycystic Ovary SyndromeRosiglitazoneTestosteroneThiazolidinedionesVitamin B 12

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

15618250

Citation

Kilicdag, Esra Bulgan, et al. "Homocysteine Levels in Women With Polycystic Ovary Syndrome Treated With Metformin Versus Rosiglitazone: a Randomized Study." Human Reproduction (Oxford, England), vol. 20, no. 4, 2005, pp. 894-9.
Kilicdag EB, Bagis T, Zeyneloglu HB, et al. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. Hum Reprod. 2005;20(4):894-9.
Kilicdag, E. B., Bagis, T., Zeyneloglu, H. B., Tarim, E., Aslan, E., Haydardedeoglu, B., & Erkanli, S. (2005). Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. Human Reproduction (Oxford, England), 20(4), 894-9.
Kilicdag EB, et al. Homocysteine Levels in Women With Polycystic Ovary Syndrome Treated With Metformin Versus Rosiglitazone: a Randomized Study. Hum Reprod. 2005;20(4):894-9. PubMed PMID: 15618250.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. AU - Kilicdag,Esra Bulgan, AU - Bagis,Tayfun, AU - Zeyneloglu,Hulusi B, AU - Tarim,Ebru, AU - Aslan,Erdogan, AU - Haydardedeoglu,Bulent, AU - Erkanli,Serkan, Y1 - 2004/12/23/ PY - 2004/12/25/pubmed PY - 2005/7/1/medline PY - 2004/12/25/entrez SP - 894 EP - 9 JF - Human reproduction (Oxford, England) JO - Hum Reprod VL - 20 IS - 4 N2 - BACKGROUND: Elevated levels of plasma homocysteine (Hcy) have been implicated as a significant risk factor for cardiovascular disease. Although long-term treatment with metformin can increase Hcy levels in patients with type II diabetes mellitus or coronary heart disease, it is becoming an increasingly accepted and widespread medication in polycystic ovary syndrome (PCOS). In the literature, only one study has demonstrated that metformin increases Hcy levels in PCOS patients, but the effect of other insulin sensitizers on Hcy levels have not been reported previously in women with PCOS. We aimed to assess the effects of metformin and rosiglitazone on plasma Hcy levels in patients with PCOS. METHODS: Thirty women were randomized to two groups: 15 women in group 1 received 850 mg of metformin twice daily for 3 months. In group 2, 15 women received 4 mg of rosiglitazone for 3 months. In both groups, body mass index, menstrual pattern, and plasma total Hcy, insulin, glucose and lipid metabolism parameters were recorded at baseline and at 3 months. RESULTS: Hcy levels increased from 8.93+/-0.49 to 11.26+/-0.86 micromol/l (P = 0.002) and from 10.70+/-0.86 to 12.36+/-0.81 micromol/l (P = 0.01) in the metformin and rosiglitazone groups, respectively. Apolipoprotein (Apo) A1 levels increased from 127.10+/-6.85 to 145.7+/-7.18 mg/dl (P = 0.018) in the metformin group. Total cholesterol (total-C), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), lipoprotein (a) and Apo B levels decreased in the metformin group, but the change was not significant. Total-C levels decreased from 161.15+/-8.94 to 150.23+/-8.73 mg/dl (P = 0.026), HDL-C decreased from 43.13+/-2.65 to 39.15+/-2.52 mg/dl (P = 0.005) and LDL-C levels decreased from 93.83+/-6.06 to 80.7+/-2.30 mg/dl (P = 0.021) in the rosiglitazone group. CONCLUSION: Treatment with insulin sensitizers in women with PCOS may lead to increases in Hcy levels. SN - 0268-1161 UR - https://www.unboundmedicine.com/medline/citation/15618250/Homocysteine_levels_in_women_with_polycystic_ovary_syndrome_treated_with_metformin_versus_rosiglitazone:_a_randomized_study_ DB - PRIME DP - Unbound Medicine ER -